HK1044549A1 - Compounds with inhibit leukocyte adhesion mediatedby vla-4. - Google Patents

Compounds with inhibit leukocyte adhesion mediatedby vla-4.

Info

Publication number
HK1044549A1
HK1044549A1 HK02106216A HK02106216A HK1044549A1 HK 1044549 A1 HK1044549 A1 HK 1044549A1 HK 02106216 A HK02106216 A HK 02106216A HK 02106216 A HK02106216 A HK 02106216A HK 1044549 A1 HK1044549 A1 HK 1044549A1
Authority
HK
Hong Kong
Prior art keywords
mediatedby
vla
compounds
leukocyte adhesion
inhibit leukocyte
Prior art date
Application number
HK02106216A
Other versions
HK1044549B (en
Inventor
Susan Ashwell
Reinhardt Bernhard Baudy
Michael A Pleiss
Dimitrios Sarantakis
Eugene D Thorsett
Original Assignee
Elan Pharm Inc
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, Wyeth Corp filed Critical Elan Pharm Inc
Publication of HK1044549A1 publication Critical patent/HK1044549A1/en
Publication of HK1044549B publication Critical patent/HK1044549B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
HK02106216.3A 1999-01-25 2002-08-23 Compounds with inhibit leukocyte adhesion mediated by vla-4 HK1044549B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23747399A 1999-01-25 1999-01-25
PCT/US2000/001603 WO2000043415A1 (en) 1999-01-25 2000-01-21 Compounds which inhibit leukocyte adhesion mediated by vla-4

Publications (2)

Publication Number Publication Date
HK1044549A1 true HK1044549A1 (en) 2002-10-25
HK1044549B HK1044549B (en) 2005-05-27

Family

ID=22893870

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02106216.3A HK1044549B (en) 1999-01-25 2002-08-23 Compounds with inhibit leukocyte adhesion mediated by vla-4

Country Status (9)

Country Link
EP (1) EP1150997A1 (en)
JP (1) JP2002539080A (en)
CN (1) CN1185250C (en)
AR (1) AR029611A1 (en)
AU (1) AU3348700A (en)
CA (1) CA2359114A1 (en)
HK (1) HK1044549B (en)
MX (1) MXPA01007394A (en)
WO (1) WO2000043415A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2200617B1 (en) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. DERIVATIVES OF UREA AS ANTAGONISTS OF INTEGRINAS ALPHA 4.
JP2005022976A (en) * 2001-07-18 2005-01-27 Ajinomoto Co Inc Carboxylic acid derivative
WO2003050261A2 (en) 2001-12-10 2003-06-19 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
CA2514117A1 (en) * 2003-01-24 2004-08-12 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
CA2522084A1 (en) * 2003-04-10 2004-10-28 Amgen Inc. Cyclic amine derivatives and their use in the treatment of inflammation-related disorders mediated by bradykinin
WO2018053446A1 (en) 2016-09-18 2018-03-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Yap1 inhibitors that target the interaction of yap1 with oct4
CN111989100A (en) 2018-03-14 2020-11-24 H·李·莫菲特癌症中心研究有限公司 YAP1 inhibitors targeting YAP1 interaction with OCT4

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1102316A (en) * 1975-12-09 1981-06-02 Shosuke Okamoto N su2 xx-arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
FR2679903B1 (en) * 1991-08-02 1993-12-03 Elf Sanofi DERIVATIVES OF N-SULFONYL INDOLINE CARRYING AN AMIDIC FUNCTION, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
AU1354292A (en) * 1991-03-18 1992-10-21 Pentapharm Ag Parasubstituted phenylalanine derivates
JPH10506608A (en) * 1994-07-11 1998-06-30 アセナ ニューロサイエンシーズ，インコーポレイテッド Inhibitor of leukocyte adhesion
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
CA2291778A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
DE69833654T2 (en) * 1997-05-29 2006-12-14 Merck & Co., Inc. (A New Jersey Corp.) BIARYL ALKANIC ACIDS IN USE AS CELL ADHESION INHIBITORS
CN1133648C (en) * 1997-07-31 2004-01-07 伊兰药品公司 Subtsituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4

Also Published As

Publication number Publication date
MXPA01007394A (en) 2002-04-09
JP2002539080A (en) 2002-11-19
HK1044549B (en) 2005-05-27
AR029611A1 (en) 2003-07-10
WO2000043415A1 (en) 2000-07-27
AU3348700A (en) 2000-08-07
CN1340058A (en) 2002-03-13
CA2359114A1 (en) 2000-07-27
EP1150997A1 (en) 2001-11-07
CN1185250C (en) 2005-01-19

Similar Documents

Publication Publication Date Title
ZA986834B (en) Compounds which inhibit leukocyte adhesion mediated by VLA-4.
HK1045157A1 (en) Compounds which inhibit leukocyte adhesion mediated by vla-4
ZA986837B (en) 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4.
IL133641A0 (en) Compounds which inhibit leukocyte adhesion mediated by vla-4
AU2623900A (en) Compounds which inhibit leukocyte adhesion mediated by vla-4
IL133635A0 (en) Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
ZA986827B (en) Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4.
MXPA01009505A (en) Permeability-modulated carrier referencing.
MXPA01013406A (en) Vla-4 inhibitor compounds.
ZA200108968B (en) New compounds.
ZA200203799B (en) Antithrombotic compound.
GB9924797D0 (en) Compound
HK1044549A1 (en) Compounds with inhibit leukocyte adhesion mediatedby vla-4.
HK1046146A1 (en) Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4.
GB9920919D0 (en) Novel compound
AU6517800A (en) Ntr3, a member of the tnf-receptor supergene family
GB9907861D0 (en) The tracker
GB9921928D0 (en) Compound
GB0031557D0 (en) Compound
GB9914342D0 (en) Compound
GB0031563D0 (en) Compound
ZA200201714B (en) Novel compound F-15078.
GB9929255D0 (en) Compound
GB9921929D0 (en) Compound
GB9924965D0 (en) Compound

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090121